[go: up one dir, main page]

BRPI1007518A2 - uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia - Google Patents

uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia

Info

Publication number
BRPI1007518A2
BRPI1007518A2 BRPI1007518-6A BRPI1007518A BRPI1007518A2 BR PI1007518 A2 BRPI1007518 A2 BR PI1007518A2 BR PI1007518 A BRPI1007518 A BR PI1007518A BR PI1007518 A2 BRPI1007518 A2 BR PI1007518A2
Authority
BR
Brazil
Prior art keywords
eicopentanoic
hypertriglyceridemia
acid
treatment
ethyl ester
Prior art date
Application number
BRPI1007518-6A
Other languages
English (en)
Inventor
Manku Mehar
Osterloh Ian
Wicker Pierre
Braeckman Rene
Soni Paresh
Original Assignee
Amarin Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007518(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharma, Inc. filed Critical Amarin Pharma, Inc.
Publication of BRPI1007518A2 publication Critical patent/BRPI1007518A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1007518-6A 2009-02-10 2010-02-09 uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia BRPI1007518A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US61/151.291 2009-02-10
US17375509P 2009-04-29 2009-04-29
US61/173.755 2009-04-29
PCT/US2010/023638 WO2010093634A1 (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Publications (1)

Publication Number Publication Date
BRPI1007518A2 true BRPI1007518A2 (pt) 2018-02-20

Family

ID=42102041

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007518-6A BRPI1007518A2 (pt) 2009-02-10 2010-02-09 uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia

Country Status (23)

Country Link
US (29) US8293727B2 (pt)
EP (5) EP3865128A1 (pt)
KR (2) KR101383006B1 (pt)
AU (1) AU2010213899B2 (pt)
BR (1) BRPI1007518A2 (pt)
CA (3) CA3008079C (pt)
CY (2) CY1122629T1 (pt)
DK (3) DK2596786T3 (pt)
ES (3) ES2426132T3 (pt)
HR (3) HRP20130811T1 (pt)
HU (1) HUE048299T2 (pt)
LT (2) LT3037089T (pt)
MX (1) MX2011008448A (pt)
NZ (1) NZ594395A (pt)
PH (1) PH12015500407B1 (pt)
PL (3) PL2395991T3 (pt)
PT (3) PT2596786T (pt)
RU (2) RU2505292C2 (pt)
SG (3) SG173612A1 (pt)
SI (3) SI2596786T1 (pt)
SM (3) SMT202000078T1 (pt)
WO (1) WO2010093634A1 (pt)
ZA (1) ZA201105612B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP2376077B1 (en) 2009-01-12 2017-03-15 Biokier Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
BRPI1007518A2 (pt) 2009-02-10 2018-02-20 Amarin Pharma, Inc. uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
MY205872A (en) 2009-04-29 2024-11-18 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising omega-3 fatty acids
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010260129B2 (en) 2009-06-15 2014-05-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels
EA201290158A1 (ru) 2009-09-23 2012-08-30 Биокиер, Инк. Композиция и способ лечения диабета
BR112012006692B8 (pt) 2009-09-23 2021-05-25 Amarin Corp Plc composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato
US20110178105A1 (en) 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
BR112012022336A2 (pt) * 2010-03-04 2020-07-21 Amarin Pharma, Inc. composições e seus usos para tratar e/ou prevenir doença cardiovascular
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) * 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
PT2800563T (pt) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre
US9827219B2 (en) * 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
WO2014189386A2 (en) * 2012-02-14 2014-11-27 Photonz Corporation Method for supervising consumption of a medical food for prevention and/or management of a disease or condition
WO2013169797A1 (en) 2012-05-07 2013-11-14 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
CN104271127A (zh) * 2012-05-15 2015-01-07 持田制药株式会社 高血中高敏c反应蛋白患者的心血管疾病初级预防剂
US20130324607A1 (en) * 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
PT4338805T (pt) 2012-06-29 2025-09-02 Amarin Pharmaceuticals Ie Ltd Éster etílico do ácido eicosapentanoico para utilização na redução do risco de enfarte do miocárdio não fatal num indivíduo em terapia com estatina
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
EP2902020A4 (en) * 2012-09-28 2016-03-23 Mochida Pharm Co Ltd COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (ko) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (ja) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 白金錯体およびデバイス
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016175575A1 (ko) * 2015-04-30 2016-11-03 엘지전자(주) 블루투스 메쉬 네트워크를 이용하여 데이터를 송수신하기 위한 방법 및 장치
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP3687538B1 (en) 2017-10-30 2024-04-17 Montreal Heart Institute Methods of treating elevated plasma cholesterol
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PL4056176T3 (pl) * 2018-09-24 2024-08-26 Amarin Pharmaceuticals Ireland Limited Sposoby zmniejszania ryzyka zdarzeń krążeniowo-naczyniowych u osobnika
JP2022543136A (ja) * 2019-08-05 2022-10-07 アローヘッド ファーマシューティカルズ インコーポレイテッド Ａｐｏｃ３関連疾患および障害の処置のための方法
KR20220122616A (ko) 2019-11-12 2022-09-02 애머린 파마슈티칼스 아일랜드 리미티드 심방 세동 및/또는 심방 조동을 갖는 대상체에서 심혈관 사건의 위험을 감소시키는 방법
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited METHODS TO REDUCE THE RISK OF HEART FAILURE

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (ja) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA1338683C (en) 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (en) * 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
NZ334852A (en) 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JP4309045B2 (ja) 1997-10-30 2009-08-05 森下仁丹株式会社 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法
KR100587551B1 (ko) 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
ES2304061T3 (es) 1999-07-28 2008-09-01 Swiss Caps Rechte Und Lizenzen Ag Preparado para el empleo como medicamento y/o para el complemento de articulos comestibles.
AU6813700A (en) 1999-08-30 2001-03-26 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
DE60022987T2 (de) 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
SK1742003A3 (en) 2000-08-15 2004-06-08 Pfizer Prod Inc Therapeutic combinations of a CETP inhibitor and atorvastatin
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
HUP0200686A2 (hu) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
JP4398862B2 (ja) 2002-08-20 2010-01-13 興和株式会社 軟カプセル剤
EP1564278B1 (en) 2002-11-22 2018-01-10 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
CN1756545A (zh) 2003-03-05 2006-04-05 索尔瓦药物有限公司 ω－3－脂肪酸在治疗糖尿病患者中的应用
NZ541516A (en) 2003-03-18 2008-05-30 Novartis Ag Compositions comprising fatty acids and amino acids
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
WO2005114190A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
BRPI0514189A (pt) 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
KR20070053283A (ko) 2004-09-13 2007-05-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US20070292523A1 (en) 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
EP1833313A2 (en) 2004-10-15 2007-09-19 Corporation Limited Photonz Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
WO2006062748A2 (en) 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
EA200701913A1 (ru) 2005-03-08 2008-08-29 Релайэнт Фармасьютикалз, Инк. Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
TWI412361B (zh) 2005-07-08 2013-10-21 Mochida Pharm Co Ltd 預防心血管症候用組成物
RU2290185C1 (ru) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
JP2009502950A (ja) 2005-07-28 2009-01-29 レリアント ファーマスーティカルズ インコーポレイテッド ジヒドロピリジンカルシウムチャネルブロッカー及びω３脂肪酸を用いた治療法、並びにそれらの混合生成物
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
WO2007051065A2 (en) 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
BRPI0618455A2 (pt) 2005-11-11 2011-08-30 Mochida Pharm Co Ltd composição de geléia
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
PL1800675T4 (pl) 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
EP2526937A1 (en) * 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
CA2653787C (en) 2006-05-31 2016-06-21 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US8877465B2 (en) 2006-07-05 2014-11-04 Photonz Corporation Limited Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (ru) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
EP2119443B1 (en) 2007-01-17 2014-08-20 Mochida Pharmaceutical Co., Ltd. Composition for prevention or treatment of disease associated with thrombus or embolus
US20100055175A1 (en) 2007-03-06 2010-03-04 James Nugent Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2009004999A1 (ja) 2007-06-29 2009-01-08 Takeda Pharmaceutical Company Limited シームレスカプセル
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
CA2724983A1 (en) 2008-05-20 2009-11-26 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
BRPI1007518A2 (pt) 2009-02-10 2018-02-20 Amarin Pharma, Inc. uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010260129B2 (en) 2009-06-15 2014-05-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Also Published As

Publication number Publication date
SG10201610916SA (en) 2017-02-27
US8440650B1 (en) 2013-05-14
ES2426132T3 (es) 2013-10-21
CA2751576C (en) 2018-07-03
CA2751576A1 (en) 2010-08-19
EP3037089B1 (en) 2019-11-27
US20130004568A1 (en) 2013-01-03
HK1226307A1 (en) 2017-09-29
PT2596786T (pt) 2020-03-04
US8399446B2 (en) 2013-03-19
US20120108663A1 (en) 2012-05-03
SI3037089T1 (sl) 2020-03-31
ES2768091T3 (es) 2020-06-19
US8524698B2 (en) 2013-09-03
SMT202000079T1 (it) 2020-03-13
US8293727B2 (en) 2012-10-23
US20130171250A1 (en) 2013-07-04
US20210069142A1 (en) 2021-03-11
US8324195B2 (en) 2012-12-04
CA3089847A1 (en) 2010-08-19
EP3037089A1 (en) 2016-06-29
SMT202000078T1 (it) 2020-03-13
US20210251941A1 (en) 2021-08-19
US8293728B2 (en) 2012-10-23
EP2395991A1 (en) 2011-12-21
HRP20130811T1 (en) 2013-09-30
LT2596786T (lt) 2020-01-10
PL2596786T3 (pl) 2020-06-01
AU2010213899A1 (en) 2011-08-25
US20120157530A1 (en) 2012-06-21
RU2013154780A (ru) 2015-06-20
US20240024277A1 (en) 2024-01-25
US20130004567A1 (en) 2013-01-03
US8415335B2 (en) 2013-04-09
PL2395991T3 (pl) 2013-11-29
KR101383006B1 (ko) 2014-04-08
US20120093924A1 (en) 2012-04-19
US20110288171A1 (en) 2011-11-24
US20200246300A1 (en) 2020-08-06
US20120237594A1 (en) 2012-09-20
KR20140007973A (ko) 2014-01-20
US20100311834A1 (en) 2010-12-09
US20120108660A1 (en) 2012-05-03
US20120039997A1 (en) 2012-02-16
EP2596786A1 (en) 2013-05-29
ZA201105612B (en) 2012-10-31
PT2395991E (pt) 2013-09-03
PT3037089T (pt) 2020-03-04
US8377920B2 (en) 2013-02-19
US8431560B1 (en) 2013-04-30
US20190038590A1 (en) 2019-02-07
DK2395991T3 (da) 2013-09-02
US20210046036A1 (en) 2021-02-18
HK1165698A1 (en) 2012-10-12
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
LT3037089T (lt) 2020-01-10
US8426399B2 (en) 2013-04-23
CY1122628T1 (el) 2021-03-12
RU2686315C2 (ru) 2019-04-25
KR20110110321A (ko) 2011-10-06
HUE048299T2 (hu) 2020-07-28
EP2395991B1 (en) 2013-05-29
RU2505292C2 (ru) 2014-01-27
US20170119722A1 (en) 2017-05-04
EP3865128A1 (en) 2021-08-18
US20130164375A1 (en) 2013-06-27
US8357677B1 (en) 2013-01-22
SMT201300095B (it) 2013-11-08
US20130004566A1 (en) 2013-01-03
EP2596786B1 (en) 2019-11-27
DK2596786T3 (da) 2020-02-24
US20180185320A1 (en) 2018-07-05
US20130331447A1 (en) 2013-12-12
RU2019111131A (ru) 2020-10-15
SI2596786T1 (sl) 2020-03-31
PL3037089T3 (pl) 2020-06-01
PH12015500407A1 (en) 2015-09-21
SG10201400685SA (en) 2015-01-29
CA3008079A1 (en) 2010-08-19
US8314086B2 (en) 2012-11-20
HRP20200065T1 (hr) 2020-04-03
EP3616694A1 (en) 2020-03-04
US20130005809A1 (en) 2013-01-03
HRP20200068T1 (hr) 2020-04-03
US8367652B2 (en) 2013-02-05
US8518929B2 (en) 2013-08-27
DK3037089T3 (da) 2020-01-20
NZ594395A (en) 2014-01-31
US20120108659A1 (en) 2012-05-03
SG173612A1 (en) 2011-09-29
US20130096197A1 (en) 2013-04-18
AU2010213899B2 (en) 2014-02-06
CA3089847C (en) 2024-04-09
MX2011008448A (es) 2012-02-28
PH12015500407B1 (en) 2015-09-21
US8546372B2 (en) 2013-10-01
US8318715B2 (en) 2012-11-27
RU2011137415A (ru) 2013-03-20
ES2769926T3 (es) 2020-06-29
US20130171249A1 (en) 2013-07-04
SI2395991T1 (sl) 2013-12-31
CA3008079C (en) 2020-09-22
CY1122629T1 (el) 2021-03-12
US20130017256A1 (en) 2013-01-17
WO2010093634A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
BRPI1007518A2 (pt) uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
EP2442645A4 (en) choline
BR112013011426A2 (pt) método para purificação de material lipídico
EP2498844A4 (en) IMPFSPRITZE
EP2538988A4 (en) METHOD FOR TISSUE-DECELULARIZATION
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
EP2753701A4 (en) Acyl-ACP WACHSESTERSYNTHASEN
EP2599807A4 (en) SYNTHESIS METHOD FOR A POLYCARBOXIC ACID WATER REDUCER
DK2424520T3 (da) Anvendelse af flerumættede fedtsyrer til behandling af hudinflammation
EP2421525A4 (en) NEW DICLOFEN AC FORMULATION
DK3159329T3 (da) Anvendelse af 2-hidroxyderivater af polyumættede fedtsyrer som medikamenter
CO7020930A2 (es) Métodos de formación de ésteres pinacólicos de ácido 4–cloro–2– fluoro–3–sustituido–fenilborónico y sus métodos de uso
CL2014000290A1 (es) Uso y composicion agroquimica de dibutilamidas de acido carboxilico
PL2609075T3 (pl) Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP
BR112012017535A2 (pt) uso de compostos de vanádio para cicatrização de osso
BR112013008191A2 (pt) método para produzir ésteres de ácido metacrílico
ES1072245Y (es) Dispositivo de encerrojamiento para corazon de punta movil
SMT201500327B (it) Procedimento per la preparazione di esteri di acido (5-fluoro-2-metil-3-chinolin-2-ilmetil-indol-1-il)-acetico
BR112013005473A2 (pt) painéis para as superfícies interiores dos edifícios
BR112013013224A2 (pt) processo para preparação de nebivolol
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
BRPI1014503A2 (pt) Processo para purificação de ésteres do ácido 1-metilpirazol-4-carboxílico
BR112013014291A2 (pt) formulação lipossômica de calcetrapib
FR2944063B1 (fr) Divergent deployable de propulseur

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: H01L 21/288 , H01L 31/18

Ipc: A61K 31/202 (2000.01), A61P 3/06 (2000.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.